Summary of key quarterly metrics (USD, unless noted otherwise):
- Revenue: Not reported in Q4 2025 (No product revenue yet).
- Operating income: $7,338,000 for Q4 2025 (positive due to operating activities in a low-revenue period; note that this is offset by a large net expense line and one-off items in the quarter).
- Net income: -$6,254,893 for Q4 2025 (YoY -157.9%; QoQ -256.4%).
- EPS (diluted): -$4.01 per share for Q4 2025 (YoY -335.9%; QoQ -2,984.6%).
- EBITDA: $7,421,864 for Q4 2025 (positive, aided by non-operational items in the period).
- Cash, end of period: $5,599,074 (approx. $5.6 million).
- Cash burn from operating activities: -$1,672,649 in Q4 2025.
- Net cash provided by/used in financing activities: +$2,359,060.
- Change in cash: +$686,181.
- Weighted average shares outstanding: 1,561,000; Diluted: 1,561,000.
- G&A expenses (quarterly): approximately $4.0965 million; Selling & Marketing: $1.3639 million; Combined SG&A: ~$5.4599 million for the period (subject to rounding and line-item presentation).
- R&D: not disclosed as a separate line in the quarter (management notes emphasis on oncology; annual R&D spend disclosed in annual filings).
Notes: Revenue and some expense line items in the data set show signs of potential rounding or formatting inconsistencies (e.g., G&A line items that seem high given the company’s revenue profile). Management commentary in the earnings call corroborates a significant operating expense reduction for the year (approx. 26% year-over-year) with a $4.6 million noncash warrant inducement charge. The reported Q4 EBITDA and operating income illustrate the impact of one-time items and the timing of cash flows in a pre-revenue clinical-stage company.